Effect of Tongxinluo Capsules on Use of Anti-ischemic Drugs in Patients with Chronic Coronary Syndrome of Qi Deficiency and Blood Stasis： A Multicenter， Prospective Cohort Study
10.13422/j.cnki.syfjx.20250392
- VernacularTitle:通心络胶囊对气虚血瘀型慢性冠脉综合征患者抗缺血药物使用的影响： 一项多中心、前瞻性队列研究
- Author:
Chenhao ZHANG
1
;
Jia WANG
1
;
Yiying LIU
1
;
Xiaohe YANG
1
;
Xuesen WANG
1
;
Meili GAO
2
;
Yu DONG
3
;
Xiaotao LI
1
Author Information
1. Wangjing Hospital of China Academy of Chinese Medical Sciences，Beijing 100102，China
2. Shunyi Hospital of Beijing Hospital of Traditional Chinese Medicine，Beijing 101300，China
3. Guanganmen Hospital of China Academy of Chinese Medical Sciences，Beijing 100053，China
- Publication Type:Journal Article
- Keywords:
Tongxinluo capsules;
Qi deficiency and blood stasis type;
chronic coronary syndrome;
anti-ischemic drugs;
prospective cohort study
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(23):149-156
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effect of Tongxinluo capsules on the use of anti-ischemic drugs in patients with chronic coronary syndrome （CCS） of Qi deficiency and blood stasis. MethodA multicenter，prospective cohort study was conducted，with Tongxinluo capsules intervention as the exposure factor. Patients were divided into an exposed group （combination of traditional Chinese and western medicine） and a non-exposed group （western medicine alone），and followed up for one year. The use of anti-ischemic drugs was observed on the day of enrollment and at 3，6，12 months. ResultA total of 186 patients were enrolled，with 128 in the exposed group and 58 in the non-exposed group. There were no statistically significant differences in baseline characteristics between the two groups. At the 3-month follow-up，the types of first-line anti-ischemic drugs used in the exposed group were significantly fewer than those in the non-exposed group （P<0.01），and this difference remained statistically significant at 6 months （P<0.05） but was no longer significant at 12 months. At the 3- and 6-month follow-ups，there were no significant differences between the two groups in the types of second-line anti-ischemic drugs used. However，at the 12-month follow-up，the types of second-line anti-ischemic drugs used in the exposed group were significantly fewer than those in the non-exposed group （P<0.01）. At the 3-month follow-up，both groups showed a reduction in the types of first-line anti-ischemic drugs used compared to baseline （P<0.05），with a more pronounced reduction in the exposed group （P<0.05）. At the 6-month follow-up，the exposed group showed a significant reduction in the types of second-line anti-ischemic drugs used compared to baseline （P<0.05），while no significant changes were observed in the non-exposed group. At the 12-month follow-up，the difference in the types of second-line anti-ischemic drugs between the exposed and non-exposed groups was statistically significant （P<0.05），while there was no significant difference in the types of first-line anti-ischemic drugs. ConclusionTongxinluo capsules can effectively reduce the use of anti-ischemic drugs in patients with CCS of Qi deficiency and blood stasis.
